Metabolism functions improperly when enzymes and proteins are either not produced by the body (inherited disorders), or the produced enzymes do not function the way they are meant to. Metabolic disorders occur due to buildup of proteins, lipids, glycogen, urea, calcium stones, and toxic substances among others. Each of these molecules have certain designated metabolic pathways, and metabolic agents (enzymes, proteins) at work. Inability of these agents to carry out their tasks cause buildup of the molecules in the blood and other places. Few examples of metabolic diseases include gaucher disease, hereditary tyrosinemia, hereditary orotic aciduria, and fabry disease.
Market Dynamics
Increasing inorganic growth activities such as collaborations and agreement among market players is expected to drive the market growth over the forecast period. For instance, on December 10, 2021, Eli Lilly and Company, a pharmaceutical company and Regor Therapeutics Group, a biotechnology company announced multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders. According to this agreement, Eli Lilly will have a license to select Regor intellectual property with an option to extend the license. Lilly will be responsible for clinical development, manufacturing and commercialization worldwide, except for People's Republic of China, Macau, Hong Kong and Taiwan.
Furthermore, market players are increasingly focusing on clinical trials for development of enzyme replacement therapy. For instance, on June 16, 2020, Sanofi, a global biopharmaceutical company announced the results for investigational enzyme replacement therapy (ERT), avalglucosidase alfa that showed clinically meaningful improvement in critical manifestations (respiratory impairment and decreased mobility) of late-onset Pompe disease (LOPD), according to results from the Phase 3 trial. Avalglucosidase alfa met the primary endpoint demonstrating non-inferiority in improving respiratory function compared to alglucosidase alfa (standard of care) in patients with LOPD.
Key features of the study:
- This report provides an in-depth analysis of the global metabolism drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global metabolism drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Merck & Co., Inc., Novartis AG, Amicus Therapeutics, AstraZeneca Plc, Boehringer Ingelheim, Shire Plc, Sanofi Genzyme, BioMarin Pharmaceutical, Inc., Horizon Pharma Plc, and GlaxoSmithKline Plc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global metabolism drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global metabolism drugs market
Detailed Segmentation:
- Global Metabolism Drugs Market, By Therapy Type:
- Enzyme Replacement Therapy
- Substrate Reduction Therapy
- Small Molecule Drugs
- Others
- Global Metabolism Drugs Market, By Application:
- Glycogen Metabolism Disease
- Lipid Metabolism Disease
- Amino Acid Metabolism Disease
- Others
- Global Metabolism Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Metabolism Drugs Market, By Region:
- North America
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Merck & Co., Inc. *
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Amicus Therapeutics
- AstraZeneca Plc
- Boehringer Ingelheim
- Shire Plc
- Sanofi Genzyme
- BioMarin Pharmaceutical, Inc.
- Horizon Pharma Plc
- GlaxoSmithKline Plc.
“*” marked represents similar segmentation in other categories in the respective section.